Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A single-center retrospective cohort study with clear findings on EGFR mutation subtypes and TKI sensitivity in a defined population, but limited by retrospective design, lack of survival or clinical outcome detail, and modest sample sizes for the key comparison groups.
A narrative review synthesizing preliminary open-label clinical evidence and putative mechanisms without new empirical data; the source itself acknowledges small sample sizes, lack of controlled trials, and unresolved safety and dosing questions, positioning propofol as a candidate for future study rather than an established therapeutic.